Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Capital Expenditures (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Capital Expenditures for 15 consecutive years, with $11.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures rose 33.49% to $11.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $12.8 million, a 17.73% decrease, with the full-year FY2024 number at $10.1 million, down 30.5% from a year prior.
  • Capital Expenditures was $11.0 million for Q3 2025 at Usana Health Sciences, up from $32000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $11.0 million in Q3 2025 to a low of -$3.1 million in Q2 2024.
  • A 5-year average of $2.8 million and a median of $1.6 million in 2021 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: surged 2562.8% in 2022, then crashed 380.94% in 2023.
  • Usana Health Sciences' Capital Expenditures stood at $1.6 million in 2021, then surged by 538.45% to $10.2 million in 2022, then decreased by 28.17% to $7.3 million in 2023, then plummeted by 75.4% to $1.8 million in 2024, then surged by 508.49% to $11.0 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Capital Expenditures are $11.0 million (Q3 2025), $32000.0 (Q2 2025), and $31000.0 (Q1 2025).